Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOEL VANDERSLUIS

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1114922390
CMS profile
993288
Location
DAYTON, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$7,551.68

175 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 175 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOEL VANDERSLUIS

NPI 1114922390 · CMS profile ID 993288

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

DAYTON, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 175 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1114922390?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOEL VANDERSLUIS, NPI 1114922390, CMS profile ID 993288. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 175 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1114922390?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). JOEL VANDERSLUIS, NPI 1114922390, CMS profile ID 993288. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 175 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1114922390?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
JOEL VANDERSLUIS, NPI 1114922390, CMS profile ID 993288, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 175 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1114922390?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

175 matching records · $7,551.68 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 175 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 175.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ACADIA Pharmaceuticals Inc $16.3106/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838023827 CMS
AbbVie Inc. $4.6706/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796194423 CMS
AbbVie Inc. $5.5506/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796194425 CMS
Novartis Pharmaceuticals Corporation $5.6406/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813333285 CMS
Novartis Pharmaceuticals Corporation $12.8706/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813333289 CMS
AbbVie Inc. $8.2306/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796194421 CMS
GENZYME CORPORATION $24.7206/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843502113 CMS
SK Life Science, Inc. $20.9206/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826854573 CMS
Allergan, Inc. $14.9306/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792973345 CMS
Neurocrine Biosciences, Inc. $12.6306/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837820707 CMS
Biohaven Pharmaceuticals, Inc. $19.7105/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852647841 CMS
Biohaven Pharmaceuticals, Inc. $16.1805/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852647839 CMS
Teva Pharmaceuticals USA, Inc. $13.5005/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839594267 CMS
AbbVie Inc. $1,440.0005/25/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796194419 CMS
Avanir Pharmaceuticals, Inc. $11.4205/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801027991 CMS
EMD Serono, Inc. $15.1605/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849190473 CMS
Genentech USA, Inc. $17.0005/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835927495 CMS
AbbVie Inc. $14.5605/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796194417 CMS
UCB, Inc. $14.7105/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807357097 CMS
Novartis Pharmaceuticals Corporation $15.1605/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813333281 CMS
AbbVie Inc. $13.2505/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796194415 CMS
GENZYME CORPORATION $29.5405/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843502089 CMS
SK Life Science, Inc. $10.2105/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826854563 CMS
AbbVie Inc. $19.6004/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796194413 CMS
Biohaven Pharmaceuticals, Inc. $19.4104/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852647837 CMS
AbbVie Inc. $6.8404/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796194411 CMS
Janssen Pharmaceuticals, Inc $14.2904/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787850483 CMS
Allergan, Inc. $21.0904/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792973341 CMS
Allergan, Inc. $2.0704/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792973343 CMS
UCB, Inc. $18.5704/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807334699 CMS
Novartis Pharmaceuticals Corporation $15.3704/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813333277 CMS
SK Life Science, Inc. $20.7004/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826854549 CMS
Amgen Inc. $18.8604/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825425521 CMS
Lilly USA, LLC $14.7404/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818569511 CMS
Genentech USA, Inc. $17.3804/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835927493 CMS
Novartis Pharmaceuticals Corporation $18.8004/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813333273 CMS
Biohaven Pharmaceuticals, Inc. $17.2504/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852647835 CMS
GENZYME CORPORATION $20.3604/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843502081 CMS
Celgene Corporation $15.6703/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783727367 CMS
AbbVie Inc. $3.1103/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796194409 CMS
CSL Behring $18.5003/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820279513 CMS
Eisai Inc. $14.5803/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 817880447 CMS
Novartis Pharmaceuticals Corporation $13.9803/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813333245 CMS
Genentech USA, Inc. $20.9603/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835927489 CMS
Teva Pharmaceuticals USA, Inc. $13.5303/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839594265 CMS
EMD Serono, Inc. $17.2103/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849173415 CMS
AbbVie Inc. $16.6203/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796194407 CMS
AbbVie Inc. $4.5603/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796194405 CMS
Sunovion Pharmaceuticals Inc. $20.5903/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821640446 CMS
ARBOR PHARMACEUTICALS, INC. $50.0003/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830966017 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,079.27 151
PY2020 $3,292.33 70
PY2021 $7,551.68 175
PY2022 $2,826.71 165
PY2023 $2,804.79 133
PY2024 $2,831.49 146
PY2025 $4,304.55 148

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,229,670.51 31
PY2024 Principal investigator $1,736,046.73 28
PY2023 Recipient $2,385.20 3
PY2023 Principal investigator $2,946,983.06 51
PY2022 Recipient $4,394.00 4
PY2022 Principal investigator $2,788,057.03 25
PY2021 Recipient $23,636.33 2
PY2021 Principal investigator $2,094,653.18 59
PY2020 Recipient $776.59 1
PY2020 Principal investigator $725,058.91 38
PY2019 Recipient $258.36 1
PY2019 Principal investigator $803,345.16 81

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

31 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Ipsen Innovation $2,310.00 12/23/2025 Non-covered Recipient Entity
Neurology Diagnostics, Inc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287736
Principal investigator 1 Ipsen Innovation $735.00 12/23/2025 Non-covered Recipient Entity
Neurology Diagnostics, Inc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287740
Principal investigator 1 Ipsen Innovation $735.00 12/23/2025 Non-covered Recipient Entity
Neurology Diagnostics, Inc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287742
Principal investigator 1 Ipsen Innovation $3,336.20 12/19/2025 Non-covered Recipient Entity
Neurology Diagnostics, Inc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287734
Principal investigator 1 Ipsen Innovation $3,628.80 12/19/2025 Non-covered Recipient Entity
Neurology Diagnostics, Inc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287738
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,201.99 10/27/2025 Non-covered Recipient Entity
Neurology Diagnostics, Inc
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild-to-Moderate Alzheimers Disease (MINDSET 1) No dispute reported 06/30/2026 1235995431
Principal investigator 1 Ipsen Innovation $3,000.00 09/17/2025 Non-covered Recipient Entity
Neurology Diagnostics, Inc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287724
Principal investigator 1 Ipsen Innovation $8,500.00 09/17/2025 Non-covered Recipient Entity
Neurology Diagnostics, Inc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287726
Principal investigator 1 Ipsen Innovation $12,000.00 09/17/2025 Non-covered Recipient Entity
Neurology Diagnostics, Inc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287728
Principal investigator 1 Ipsen Innovation $800.00 09/17/2025 Non-covered Recipient Entity
Neurology Diagnostics, Inc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287730
Principal investigator 1 Ipsen Innovation $3,000.00 09/17/2025 Non-covered Recipient Entity
Neurology Diagnostics, Inc
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184287732
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $25,703.43 07/14/2025 Non-covered Recipient Entity
Neurology Diagnostics, Inc
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild-to-Moderate Alzheimers Disease (MINDSET 1) No dispute reported 06/30/2026 1235995433
Principal investigator 1 UCB SA $7,085.00 06/24/2025 Non-covered Recipient Entity
Neurology Diagnostics, Inc
A MULTICENTER PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF UCB0022 IN STUDY PARTICIPANTS WITH ADVANCED Parkinsons DISEASE No dispute reported 06/30/2026 1246657980
Principal investigator 1 Amgen Inc. $40,430.40 06/05/2025 Non-covered Recipient Entity
NEUROLOGY DIAGNOSTICS INC
A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety Between ABP 692 and Ocrevus (Ocrelizumab) in Subjects With Relapsing-remitting Multiple Sclerosis No dispute reported 06/30/2026 1246645032
Principal investigator 1 ABBVIE INC. $824.00 05/08/2025 Non-covered Recipient Entity
NEUROLOGY DIAGNOSTICS INC
A Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ABBV-552 in Participants with Mild Alzheimer's Disease No dispute reported 06/30/2026 1202484571
Principal investigator 1 Eli Lilly and Company $199.02 04/23/2025 Non-covered Recipient Entity
NEUROLOGY DIAGNOSTICS INC
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187887436
Principal investigator 1 Eli Lilly and Company $203,561.00 04/07/2025 Non-covered Recipient Entity
NEUROLOGY DIAGNOSTICS INC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE-FINDING STUDY EVALUATING LY3848575 IN CHRONIC NEUROPATHIC PAIN ASSOCIATED WITH DISTAL SENSORY POLYNEUROPATHY No dispute reported 06/30/2026 1187885664
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,540.00 04/04/2025 Non-covered Recipient Entity
Advarra
A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) No dispute reported 06/30/2026 1235999225
Principal investigator 1 Eli Lilly and Company $883.10 02/25/2025 Non-covered Recipient Entity
NEUROLOGY DIAGNOSTICS INC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187885904
Principal investigator 1 ABBVIE INC. $2,000.00 02/13/2025 Non-covered Recipient Entity
NEUROLOGY DIAGNOSTICS INC
A Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ABBV-552 in Participants with Mild Alzheimer's Disease No dispute reported 06/30/2026 1202451849
Principal investigator 1 Eli Lilly and Company $3,438.15 02/10/2025 Non-covered Recipient Entity
NEUROLOGY DIAGNOSTICS INC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187887434
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $5,703.39 01/27/2025 Non-covered Recipient Entity
Neurology Diagnostics, Inc
A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) No dispute reported 06/30/2026 1235995429
Principal investigator 1 Eli Lilly and Company $741.50 01/27/2025 Non-covered Recipient Entity
NEUROLOGY DIAGNOSTICS INC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1187884434
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $17,745.00 01/24/2025 Non-covered Recipient Entity
Elias Research Associates Llc
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease Dementia No dispute reported 06/30/2026 1235997529
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $443,522.18 01/21/2025 Non-covered Recipient Entity
Neurology Diagnostics, Inc
A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) No dispute reported 06/30/2026 1235995427
Principal investigator 1 Novartis Pharmaceuticals Corporation $46,948.35 01/21/2025 Non-covered Recipient Entity
NEUROLOGY DIAGNOSTICS INC
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190304141
Principal investigator 1 Eli Lilly and Company $37,349.00 01/13/2025 Non-covered Recipient Entity
NEUROLOGY DIAGNOSTICS INC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1187885902
Principal investigator 1 Novartis Pharmaceuticals Corporation $101,519.19 01/09/2025 Non-covered Recipient Entity
NEUROLOGY DIAGNOSTICS, INC
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190309694
Principal investigator 1 Eli Lilly and Company $112,128.00 01/07/2025 Non-covered Recipient Entity
NEUROLOGY DIAGNOSTICS INC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187885662
Principal investigator 1 Eli Lilly and Company $48,274.00 01/07/2025 Non-covered Recipient Entity
NEUROLOGY DIAGNOSTICS INC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187887432
Principal investigator 1 Novartis Pharmaceuticals Corporation $90,828.81 01/07/2025 Non-covered Recipient Entity
NEUROLOGY DIAGNOSTICS, INC
AGNOS: An 18-month, Open-label, Multi-Center Study to Assess the Effect of Ofatumumab 20mg SC Monthly in Treatment Nave, Very Early Relapsing Remitting Multiple Sclerosis Patients Benchmarked Against Healthy Controls on Select Outcomes No dispute reported 06/30/2026 1190309696